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The article deals with the issue of topical use of tranexamic acid in cardiac surgery. Four
randomized, double-blind trials comparing tranexamic acid vs. placebo were identified in the
available literature (371 patients in total). In all of these studies the topical application of
tranexamic acid significantly reduced postoperative blood loss, whereas a significant reduction
of transfusion requirements was only described in one of these studies. A meta-analytic
approach confirmed a significant reduction in blood loss (in 24 h) by 321.6mL on average (95%
confidence interval 530.3mL, 112.9mL; p¼0.003). Another trial was performed to examine a
possible augmentation of systemic administration of tranexamic acid by the additional topical
application. Despite an evident tendency toward lower blood loss in the group treated also
topically, the differences between groups in this study did not reach statistical significance.
There is an apparent need for further controlled trials with larger groups of patients.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.1. Introduction
A history of preventive application of fibrinolytic inhibitors in
cardiac surgery is older than 30 years. This pharmacological
strategy is frequently used to reduce postoperative blood loss,
transfusion requirements and the frequency of early surgical
revisions for bleeding. In 2007/2008, based on the results of
Karkouti et al. [1], Mangano et al. [2] and Fergusson et al. [3], the
most effective antifibrinolytic agent – aprotinin – was suspended
from the global pharmaceutical market and it is not currently
used at all (with the exception of re-authorization for the use in
coronary artery bypass grafting in Canada, September 2011).ch Society of Cardiology.
nika, Kardiocentrum, 3. L
).Lysine analogues (tranexamic acid, e-aminocaproic acid) are an
important part of blood saving programs inmany cardiac surgery
centers [4] but the efficacy and safety profile of these drugs are
broadly investigated and discussed. While e-aminocaproic acid is
often applied in the US, the use of tranexamic acid is more
common in Canada and Europe [5]. E-aminocaproic acid is not
presently registered by the State Institute for Drug Control and
permitted for use in the Czech Republic.
2. Tranexamic acid overview
Tranexamic acid – 4-(aminomethyl)cyclohexane-1-carboxylic
acid – is a synthetic derivative of the amino acid lysine.Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
F UK a FNKV, Ruska´ 87, 100 00 Praha 10, Czech Republic.
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plasminogen which prevents its interaction with fibrin (Fig. 1).
Generally, plasminogen binds to fibrin at a lysine binding site
and is converted in the presence of tissue plasminogen acti-
vator to plasmin. Tranexamic acid blocks the lysine binding site
and prevents access of plasminogen to fibrin molecules [6,7].
Tranexamic acid is used in a variety of surgical procedures,
including cardiac surgery (both on-pump/off-pump), ortho-
pedic surgery, liver transplantation, prostatectomy, dental
surgery and gynecology. A large, randomized, double-blind
multicenter CRASH-2 trial proved that tranexamic acid
reduced all-cause mortality at 4 weeks and the death rate
due to bleeding in trauma patients [8].
Tranexamic acid is generally well tolerated but some adverse
events were reported, as well and it is necessary to take them
into consideration in everyday clinical practice. Theoretically,
due to the antifibrinolytic mechanism, there is a possibility of
an increased risk of thromboembolic events (e.g. early graft
closure in coronary artery bypass grafting, deep vein thrombo-
sis, pulmonary embolism, myocardial and cerebral infarctions),
but in practice these adverse events were reported quite rarely
[9]. Another serious adverse event recently discussed in cardiac
surgery seems to be a risk of postoperative convulsive seizures,
associated particularly with high-dose regimens [10,11]. This
epileptogenic effect of tranexamic acid may be explained by
a similarity between its molecules and the molecules of
g-aminobutyric acid (Fig. 2), which leads to the occupancy of
g-aminobutyricA brain receptors [12].Fig. 2 – Structural formulas and space-filling models of
tranexamic acid (TA) and c-aminobutyric acid (GABA).3. Systemic use of tranexamic acid
The systemic application of tranexamic acid is the most com-
mon approach in cardiac surgery. According to the availableFig. 1 – Antifibrinolytic action of tranexamic acid. A – activatio
plasminogen activator. Reproduced from Dunn CJ, Goa KL: Tr
Indications, Drugs 1999, 57(6):1005–1032, with permission fromliterature, recommended dosages vary across countries and
cardiac centers (loading intravenous dose 1–10 g, addition to
the content of the cardiopulmonary bypass circuit prime
500–2500mg, continuous infusion 200–1000mg/h) [13].4. Topical application of tranexamic acid
The topical/local application of tranexamic acid into the
pericardial cavity is not so frequent in comparison with its
systemic use. The rationale for the topical application is
based on Tabuchi et al. [14] and Khalil et al. [15] findings that
the local fibrinolytic activity in the pericardial cavity exceeds
that in the systemic circulation. A human pericardium con-
tains high levels of tissue plasminogen activator, which
under normal/physiological conditions prevents the forma-
tion of adhesions and maintains the fluidity of the pericardialn of fibrinolysis; B – inhibition of fibrinolysis. t-PA – tissue
anexamic Acid. A Review of its Use in Surgery and Other
Springer International AG (& 1999. All rights reserved).
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fibrinolytic activity.
We searched MEDLINE from 1995 to 2012 with the follow-
ing keywords: ‘‘Cardiac surgical procedures’’, ‘‘Postoperative
bleeding’’, ‘‘Antifibrinolytic agents’’, ‘‘Tranexamic acid’’ and
‘‘Topical administration’’. The studies were assessed inde-
pendently by both authors according to the methodology
proposed in the literature [16]. The criteria were as follows:
randomization, double-blinding and allocation concealment.
We identified four randomized, double-blind, controlled trials
written in English comparing the topical application of
tranexamic acid vs. placebo (Table 1) [17–20]. One study
written in the Turkish language [21] was not included in the
review and the subsequent meta-analysis because of not
fulfilling the above mentioned inclusion criteria. Additionally,
we found a meta-analysis evaluating the efficacy and safety
of the topical application of fibrinolytic inhibitors (aprotinin,
tranexamic acid) in cardiac surgery [22].
According to the trial protocols, a dose of tranexamic acid
varying from 1 g to 2.5 g in 100–250 mL of normal saline
(or just normal saline solution as a placebo) was poured into
the pericardial cavity and spread over mediastinal tissues at
the end of procedures prior to sternal closure. In all of these
trials the topical application of tranexamic acid significantly
reduced postoperative blood loss (in 24 h), but the tendency
toward reduced transfusion requirements (packed red blood
cells) reached statistical significance in only one study with
the highest concentration of tranexamic acid in the study
solution [18].
In our original research we tested a possible augmentation
of systemic administration of tranexamic acid (1 g before skin
incision and subsequently 400 mg/h, 0.5 g as a supplement
to the content of crystalloid pump prime) by the addi-
tional topical application (group A: 250 mL of normal salineþ
tranexamic acid 2.5 g, placebo group B: 250 mL of normal
saline) during heart valve surgery [23]. Although a continuous
tendency toward lower blood loss in group A was evident
(Table 2), no statistical significance was reached at any time
points (4, 8, and 24 h postoperatively). Table 2 also suggestsTable 1 – Characteristics of trials comparing topical tranexam
Study No. of
treated
patients
No. of
control
patients
Drug dose
De Bonis et al. [17] 20 20 1 g TA/100 mL
saline
Abul-Azm and
Abdullah [18]
50 50 2 g TA/100 mL
saline
Baric et al. [19] 97 96 2.5 g TA/250 m
saline
Fawzy et al. [20] 19 19 1 g TA/100 mL
saline
PRBC – packed red blood cells; TA – tranexamic acid.
n p¼0.04.
nn p¼0.01.
nnn po0.01.
nnnn po0.001.
a Comparison of three groups (aprotinin, n¼100; tranexamic acid, n¼97that in placebo group B there was greater variability in blood
loss at all time points (leading to a statistically significant
difference of variances 24 h postoperatively). No significant
difference in postoperative transfusion of packed red blood
cells was found, but the proportion of patients requiring fresh
frozen plasma after the surgery was bigger in placebo group B
(group A: n¼21, group B: n¼36, p¼0.008).5. Meta-analysis of the trials comparing the
topical application of tranexamic acid vs. placebo
5.1. Methods and statistical analysis
The meta-analysis included the four above mentioned trials,
comparing the topical application of tranexamic acid vs.
placebo (n¼371 patients in total) [17–20]. Our study [23]
investigating a possible augmentation of systemic adminis-
tration of tranexamic acid by the additional topical applica-
tion was not included because of a different way of drug
administration (systemic application of tranexamic acid in
both – treated and control – groups).
The meta-analysis focused on two primary outcomes: 24 h
postoperative chest tube drainage and the incidence of post-
operative transfusion requirements (red blood cells). The
random-effect model was used to estimate pooled treatment
effects. The results are presented in the form of weighted
mean differences (in case of blood loss) and risk ratios
(in case of transfusion needs) with corresponding 95% confi-
dence intervals (95% CI). The heterogeneity was quantified by
the I2 statistics [24]. The w2 test for heterogeneity was used to
assess whether observed differences in the study results are
compatible with the chance variation alone. In one study [20],
chest tube drainage was reported as median and minimum
and maximum. To estimate the missing mean and standard
deviation, the log-normal model was fitted via maximum
likelihood based on the three available order statistics. Since
the characteristics of variability (ranges) were only reported
for the total blood loss (not for 24 h), the calculation wasic acid vs. placebo.
Significant difference in
cumulative blood
loss (24 h)
Significant difference
in postoperative
transfusion
requirements (PRBC)
þ NS
þ þ
L þa NSa
þ NS
; placebo, n¼96).
Table 2 – Cumulative blood loss (mL) 4 h, 8 h and 24 h postoperatively (LOST study).
Postoperative time (h) Group A (n¼49) Group B (n¼51) p-Valuea p-Valueb
4 86.1 (56.1, 132.2) 135.4 (94.3, 194.4) 0.107 0.059
8 199.4 (153.4, 259.2) 261.7 (205.1, 334.0) 0.130 0.050
24 504.2 (436.0, 583.0) 569.7 (476.0, 681.7) 0.293 0.014
Data are presented as geometric means and 95% confidence intervals.
Reproduced from Spegar J, Vanek T, Snircova J, et al. Local and systemic application of tranexamic acid in heart valve surgery: a prospective,
randomized, double blind LOST study. J Thromb Thrombolysis 2011;32:303–310, with kind permission from Springer ScienceþBusiness
Media B.V.
a Test for equality of geometric means.
b Test for equality of variances.
Fig. 3 – Meta-analysis of the studies on topical application of tranexamic acid vs. placebo. Outcomes: The 24-h postoperative
chest tube drainage (mL). CI, confidence interval; SD, standard deviation.
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did not differ much from that for 24 h.
A statistical analysis was performed by statistical software
Stata, release 9.2 (Stata Corporation, College Station, TX).
p-Values less than 0.05 indicated a statistically significant
result.
In two studies the number of patients requiring transfusion
of red blood cells was not reported [18,20] and the authors
were contacted for more information, but no response
was obtained. These two studies were therefore excluded
from the part of meta-analysis concerning transfusion
needs.5.2. Results
A substantial reduction in 24-h blood loss was confirmed
in groups with topical application of tranexamic acid (Fig. 3).
The overall weighted mean difference of -321.6 mL (95% CI
530.3, 112.9) significantly differed from zero (p¼0.003).
Heterogeneity was found among the trials (I2¼90.8%,
po0.001).
The proportion of patients requiring red blood cells trans-
fusion was not significantly different (p¼0.887) between the
treated and placebo groups (Fig. 4). A variation attributable to
heterogeneity was very low.6. Discussion
This review and the subsequent meta-analysis suggest that
topical application of tranexamic acid in cardiac surgery can
significantly reduce postoperative bleeding. However, its
influence on a statistically significant reduction of transfu-
sion requirements (packed red blood cells) could not be
proven, probably due to unduly strict transfusion criteria in
the trials (not corresponding with routine everyday practice),
a limited number of study patients and a diversity in the
concentrations of study solutions.
The anticipated benefit of this way of drug delivery is that
the method seems to be both ‘‘target-directed’’ and ‘‘poten-
tially safe’’ [22]. The tranexamic acid blood levels were
measured in only one of the above mentioned trials (in a
part of topically medicated patients, n¼13) and none of these
patients had detectable tranexamic acid levels in their blood
samples [17]. The hypothesis that the pericardium acts as a
natural barrier that minimizes the rate of systemic absorp-
tion is supported by animal experimental studies with
different pharmacological agents [25,26]. In the majority of
studies the effect on the reduction of blood loss was most
pronounced in the first hours after the surgery, which is
consistent with a short half-life of tranexamic acid (3 h).
Twenty-four hours postoperatively chest tube drainage is
Fig. 4 – Meta-analysis of the studies on topical application of tranexamic acid vs. placebo. Outcomes: The incidence of
postoperative transfusion requirements (red blood cells). CI, confidence interval; SD, standard deviation.
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anti-inflammatory rather than a hemostatic effect of
tranexamic acid [27], as fibrinolytic and inflammatory sys-
tems are interlinked in the generation of pro-inflammatory
cytokines [7].7. Conclusion
In conclusion, topical use of tranexamic acid is a promising,
interesting and effective method for a significant reduction of
postoperative blood loss in patients undergoing cardiac sur-
gery, probably without increasing any additional risks to the
patients. There is an apparent need for additional rando-
mized, double-blind, controlled trials with large samples of
patients focused on the issue of right dosing of topically
applied tranexamic acid (volume and concentration), its
influence on transfusion requirements and further investiga-
tion of the drug safety.Acknowledgements
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